RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Novartis AG

A collection of news and information related to Novartis AG published by this site and its partners.

Top Novartis AG Articles see all

Displaying items 1-5
  • Pfizer walks away from AstraZeneca takeover attempt

    Pfizer walks away from AstraZeneca takeover attempt
    Pfizer Inc. said Monday that it had abandoned its current attempt to buy AstraZeneca PLC for nearly $118 billion — a deal watched warily by Maryland officials — as a deadline approached without a last-minute change of heart by the British drugmaker.
  • Asthma drug calms chronic hives, rashes

    Sufferers of chronic hives and rashes could benefit from a commonly-used asthma drug, Johns Hopkins researchers have found. Scientists found that a once-a-month dose of the drug omalizumab helped ease symptoms that standard antihistamines didn't....

    Seasonal flu vaccine may fall short

    Seasonal flu vaccine may fall short
    With all the attention given to the slow pace of distribution of the swine flu vaccine, doctors and other providers are raising concerns about a shortage of vaccine for the other flu that is expected to slam the state and country this year. Demand...

    Exclusive: U.S. approval of Merck cancer immunotherapy expected soon

    Exclusive: U.S. approval of Merck cancer immunotherapy expected soon
    U.S. regulators are likely to approve Merck & Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation. If approved by the...

    No biotech copycat drug lift off before 2017: Novartis CEO

    BASEL Switzerland (Reuters) - Swiss drugmaker Novartis AG does not expect copycat versions of biotech drugs to play an important role in the healthcare system for another three to five years, its chief executive said on Monday. Novartis' generics unit...